Devyser Diagnostics Conversion FCF

Que fait Devyser Diagnostics ? Devyser Diagnostics AB is a biotechnology company based in Hagersten, Sweden, operating within the healthcare sector. The company focuses on the development, manufacturing, and sale of genetic testing kits for routine diagnostics. It went public via an IPO on December 10, 2021, and currently employs 96 full-time staff. Devyser Diagnostics' products are utilized for complex DNA testing in areas such as hereditary diseases, oncology, and post-transplantation monitoring, aiding in the diagnosis of genetic conditions and guiding targeted cancer treatments. The company has developed and launched nearly 30 products for routine diagnostic use, including the Devyser Thrombophilia assay and Devyser Resolution XY, which analyzes chromosomes X and Y. These products are distributed directly to end customers or through hired distributors, with sales extending to over 45 countries. The company's website is www.devyser.com, and it is listed on the Stockholm Stock Exchange under the ticker DVYSR.ST. Devyser Diagnostics AB operates with a clear focus on providing diagnostic solutions that support medical professionals in identifying and managing genetic-related health issues through advanced testing technologies. Devyser Diagnostics est l'une des entreprises les plus populaires sur Eulerpool.